Nasus Pharma Announces Positive Results in Pivotal Trial of FMXIN001 Naloxone Powder-Based Nasal Spray for the Treatment of opioid overdose • Significantly higher rapid absorption
Israeli biopharmaceutical company in process of working on new mist treatment to combat spread of coronavirus in large populations For the full article click here
Nasus Pharma Announces First Clinical Data Demonstrating Efficacy of TaffixTM Intranasal Antiviral Protection Against SARS-CoV-2- in
Tel Aviv , Israel, October 13, 2020 – Nasus Pharma a privately held clinical-stagebiopharmaceutical company developing a powder-based intranasal (PBI) productportfolio to address acute medical
Nasus Pharma has developed the Taffix™- powder spray device for use as a protective mechanical barrier against viruses, e.g., SARS-CoV-2, within the nasal cavity.
Israel’s Nasus Pharma has developed a drug for intranasal delivery, a powder to cover nasal cavity which they are now using to cover against viruses.
Nasus Pharma Announces Data Demonstrating Efficacy of TaffiX™ Intranasal Antiviral Protection Against SARS-CoV-2
TEL AVIV, Israel, July 07, 2020 (GLOBE NEWSWIRE) — Nasus Pharma, a privately held clinical-stage biopharmaceutical company developing a powder-based intranasal (PBI) product portfolio to
Tel Aviv, July 2nd 2020. Tel Aviv based Nasus Pharma ( https://www.nasuspharma.com/ ) a biopharma company focused on intranasal drug delivery is pleased to announce the